Fun fact, viagra was first investigated for angina - 'heart pain' before they realised it's adverse effect.
Brilliant news, Zantrene is genuinely a pandora's box of opportunity. Just when I think the potential market share is beyond a pallatable pitch to friends and family, it opens up a market for 1.8% of US cancer market in a coformulation with a drug due to be out of patent in less than 5 years with a current cost of $300,000 US p.a. for 1-2yrs. Unreal.
I look forward to the mechanism being established for how Zantrene is cardioprotective, though I hope this stays RAC's 'secret spice'. The possibilities here are endless. Innovation to medical management of heart disease is really quite stale at the moment, this could be a game changer. The underrated spending for the current SPP fundraising, is the reformulation and investigation of new molecules... incredibly cheap with some great minds at the helm, it's a no brainer. In my view, RAC has become more of a platform than a single buy-out transcation venture.
I've got nothing left to sell bar the shirt on my back for this SPP. Incredible. GLTA
Fun fact, viagra was first investigated for angina - 'heart...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
-0.010(0.76%) |
Mkt cap ! $215.6M | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.31 | $1.23 | $212.1K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5201 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 9799 | 2 |
View Market Depth
| Last trade - 16.10pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.28 |
Change
-0.010 ( 1.17 %) |
||||
| Open | High | Low | Volume | ||
| $1.30 | $1.31 | $1.23 | 17594 | ||
| Last updated 15.52pm 29/04/2024 ? | |||||
| RAC (ASX) Chart |